Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Leukodystrophies - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Leukodystrophies - Pipeline Review, H1 2015', provides an overview of the Leukodystrophies's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Leukodystrophies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leukodystrophies and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Leukodystrophies - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Leukodystrophies and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Leukodystrophies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Leukodystrophies pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Leukodystrophies - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Leukodystrophies pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Leukodystrophies Overview 6 Therapeutics Development 7 Pipeline Products for Leukodystrophies - Overview 7 Pipeline Products for Leukodystrophies - Comparative Analysis 8 Leukodystrophies - Therapeutics under Development by Companies 9 Leukodystrophies - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Leukodystrophies - Products under Development by Companies 12 Leukodystrophies - Companies Involved in Therapeutics Development 13 ArmaGen Technologies, Inc. 13 Fate Therapeutics, Inc. 14 GlaxoSmithKline plc 15 Phenomenome Discoveries, Inc. 16 ReGenX Biosciences, LLC 17 Shire Plc 18 Leukodystrophies - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 AGT-183 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 FT-1050 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 GSK-2696274 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 PPI-1011 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 SHP-611 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Leukodystrophies - Recent Pipeline Updates 35 Leukodystrophies - Dormant Projects 38 Leukodystrophies - Discontinued Products 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 41
List of Tables Number of Products under Development for Leukodystrophies, H1 2015 7 Number of Products under Development for Leukodystrophies - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Leukodystrophies - Pipeline by ArmaGen Technologies, Inc., H1 2015 13 Leukodystrophies - Pipeline by Fate Therapeutics, Inc., H1 2015 14 Leukodystrophies - Pipeline by GlaxoSmithKline plc, H1 2015 15 Leukodystrophies - Pipeline by Phenomenome Discoveries, Inc., H1 2015 16 Leukodystrophies - Pipeline by ReGenX Biosciences, LLC, H1 2015 17 Leukodystrophies - Pipeline by Shire Plc, H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 20 Number of Products by Stage and Mechanism of Action, H1 2015 21 Number of Products by Stage and Route of Administration, H1 2015 23 Number of Products by Stage and Molecule Type, H1 2015 25 Leukodystrophies Therapeutics - Recent Pipeline Updates, H1 2015 35 Leukodystrophies - Dormant Projects, H1 2015 38 Leukodystrophies - Discontinued Products, H1 2015 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.